June 15, 2023 02:41 PM EDTUpdated June 16, 06:05 AM
Pharma

Co­herus and Ab­b­Vie set­tle Hu­mi­ra biosim­i­lar dis­pute af­ter Mark Cuban's Cost Plus Drugs an­nounce­ment

Katherine Lewin

News Reporter

Biosim­i­lars play­er Co­herus Bio­sciences has patched things up with Ab­b­Vie af­ter the phar­ma said Co­herus vi­o­lat­ed its non-ex­clu­sive li­cense to com­mer­cial­ize Yusim­ry, a biosim­i­lar of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times